CRIPTO antagonist ALK4L75A-Fc inhibits breast cancer cell plasticity and adaptation to stress

Ozlen Balcioglu1, Richard E Heinz1, David W Freeman1,2

  • 1Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.

Abstract

Insights

This study shows that targeting CRIPTO (a protein promoting cancer stemness) with ALK4L75A-Fc inhibits breast cancer cell adaptation to stress. This suggests ALK4L75A-Fc may be a potential therapy for reducing tumor growth and metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • CRIPTO is a key protein driving cancer stemness and oncogenesis.
  • A CRIPTO antagonist, ALK4L75A-Fc, was previously developed.
  • This antagonist may inhibit CRIPTO-dependent plasticity in breast cancer cells.

Purpose of the Study:

  • To investigate the effects of ALK4L75A-Fc on triple-negative breast cancer cells under nutrient deprivation and ER stress.
  • To evaluate the therapeutic potential of ALK4L75A-Fc in inhibiting cancer cell adaptation, proliferation, migration, and metastasis.

Main Methods:

  • Utilized two triple-negative breast cancer cell lines (MDA-MB-231, MDA-MB-468).
  • Assessed cell proliferation and migration in vitro using time-lapse microscopy.
  • Evaluated effects in vivo on tumor growth and metastasis in xenografts.

Main Results:

  • ALK4L75A-Fc inhibited adaptive responses to nutrient and ER stress.
  • Reduced proliferation, migration, clonogenicity, and expression of EMT and cancer stem cell markers.
  • Inhibited tumor growth and reduced metastasis in vivo.

Conclusions:

  • Targeting CRIPTO with ALK4L75A-Fc inhibits breast cancer cell adaptation to microenvironmental challenges.
  • This approach shows potential for treating breast cancer by targeting stem-like and EMT phenotypes.
  • ALK4L75A-Fc represents a candidate therapeutic strategy for breast cancer.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.4K